Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Monika Jansson

Megakaryocytes Harbour the Del(5q) Abnormality Despite Complete Clinical and Cytogenetic Remission Induced by Lenalidomide Treatment

British Journal of Haematology

Hematology

2018

English

Related publications

Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression

English

Diagnosis of Del(5q) MDS, 14 Years After JAK-2 Positive PV Appearance: Complete Remission of Both Diseases With Lenalidomide Monotherapy

Mediterranean Journal of Hematology and Infectious Diseases

Infectious Diseases

Hematology

2016

English

FISH and SNP-A Karyotyping in Myelodysplastic Syndromes: Improving Cytogenetic Detection of Del(5q), Monosomy 7, Del(7q), Trisomy 8 and Del(20q)

English

Clonal Heterogeneity in the 5q- Syndrome: P53 Expressing Progenitors Prevail During Lenalidomide Treatment and Expand at Disease Progression

Haematologica

Hematology

2009

English

Lenalidomide in 5q Minus Myelodysplastic Syndrome: How Long Is Enough?

English

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

Haematologica

Hematology

2008

English

A Critical Role for Phosphatase Haplodeficiency in the Selective Suppression of Deletion 5q MDS by Lenalidomide

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

2009

English

Low-Dose Lenalidomide Plus Cytarabine Induce Complete Remission That Can Be Predicted by Genetic Profiling in Elderly Acute Myeloid Leukemia Patients

English

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Monika Jansson

Megakaryocytes Harbour the Del(5q) Abnormality Despite Complete Clinical and Cytogenetic Remission Induced by Lenalidomide Treatment

Related publications

Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression

Diagnosis of Del(5q) MDS, 14 Years After JAK-2 Positive PV Appearance: Complete Remission of Both Diseases With Lenalidomide Monotherapy

FISH and SNP-A Karyotyping in Myelodysplastic Syndromes: Improving Cytogenetic Detection of Del(5q), Monosomy 7, Del(7q), Trisomy 8 and Del(20q)

Clonal Heterogeneity in the 5q- Syndrome: P53 Expressing Progenitors Prevail During Lenalidomide Treatment and Expand at Disease Progression

Lenalidomide in 5q Minus Myelodysplastic Syndrome: How Long Is Enough?

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

A Critical Role for Phosphatase Haplodeficiency in the Selective Suppression of Deletion 5q MDS by Lenalidomide

Low-Dose Lenalidomide Plus Cytarabine Induce Complete Remission That Can Be Predicted by Genetic Profiling in Elderly Acute Myeloid Leukemia Patients

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS